

# Payments to Healthcare Professionals

Collaboration between the pharmaceutical industry and Healthcare Professionals (HCPs) or Healthcare Organizations (HCOs) or Patient Organizations (PO) benefit patients. It is a relationship that has delivered numerous break-through medicines and changed the way many diseases impact patients' lives. Our work together includes a range of activities from clinical research to sharing best clinical practice. As an industry we make payments or 'transfers of value' to Healthcare Professionals and Organizations to compensate them for the time spent working with Novartis.

Bringing greater transparency to this already well-regulated relationship builds understanding of this collaboration and addresses public concerns about interactions between the medical community and the pharmaceutical industry. We believe that openly communicating payments helps foster trust with patients, Healthcare Professionals, government officials and the public, and supports our overall commitment to data transparency and high ethical business standards. Novartis has long been dedicated to improving [clinical trial data transparency](#) and discloses [relationships with patient organizations](#).

In several countries, we publish payments to Healthcare Professionals, Healthcare Organizations and Patient Organizations in line with local laws or regulations.

## About our Reporting Practices

### Europe

Across Europe, Novartis discloses annually payments and other transfers of value in line with the [European Federation of Pharmaceutical Industries and Associations \(EFPIA\) Disclosure Code](#) and its local transpositions. [The EFPIA Disclosure Code 2025 Self-Certification Letter \(PDF 0.4 MB\)](#) signed by Patrick Horber, Novartis President, International, confirms the application of the [principles of the EFPIA Disclosure Code](#). The letter from previous year is available [here \(PDF 0.1 MB\)](#).

### United States

Under the Sunshine Act, Novartis is required each year to submit data to the [Centers for Medicare and Medicaid Services \(CMS\)](#) Open Payments program (commonly known as [the Sunshine Act](#)) as an applicable manufacturer. CMS collects information about certain payments and other transfers of value from applicable manufacturers and group purchasing organizations (GPOs) to physicians and teaching hospitals. Open Payments is the federally run transparency program that collects information about these financial relationships and makes it available to the public annually through the [CMS Open Payments website](#).

[Read more about our Payments to Healthcare Professionals in the United States.](#)

### Rest of the world

In addition to the EFPIA countries and the United States, we publicly disclose transfers of value in Australia, Brazil, Colombia, Canada, Israel, Japan and New Zealand. In Chile, India, Indonesia, Pakistan, Philippines and Saudi Arabia, transfers of value are reported to the government. In South Korea and Turkey, transfers of value are gathered and shared with the Ministry of Health upon request.

## All Disclosure Reports

### Australia

Disclosure Report

[English](#)

### Austria

Disclosure Report

Disclosure Report

Novartis

Sandoz

## **Belgium**

Disclosure Report

Novartis

French

Dutch

Sandoz

French

Dutch

## **Bosnia and Herzegovina**

Below is the disclosure information for Bosnia and Herzegovina in English as per EFPIA regulations. In case of questions please [contact us](#).

---

## **2024**

Novartis

Disclosure Report (PDF 0.2 MB)

Methodological Note (PDF 0.4 MB)

## **2023**

Novartis

Disclosure Report (PDF 0.2 MB)

Methodological Note (PDF 0.3 MB)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

## **2022**

Novartis

Disclosure Report (PDF 0.4 MB)

Methodological Note (PDF 0.3 MB)

Sandoz

Disclosure Report (PDF 0.2 MB)

Methodological Note (PDF 0.3 MB)

## **Brazil**

Disclosure Report

[Portuguese](#)

## **Bulgaria**

Disclosure Report

[Novartis](#)

[Sandoz](#)

## **Canada**

Disclosure Report

Novartis

[English](#)

[French](#)

Sandoz

[English](#)

[French](#)

## **Colombia**

Disclosure Report

[Spanish](#)

## **Croatia**

Sukladno pravilima EFPIA udruženja niže su navedeni podaci na hrvatskom jeziku za objavu za Hrvatsku. U slučaju pitanja molimo Vas da nas [kontaktirate](#).

---

## **2024**

Novartis

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

## **2023**

Novartis

[Disclosure Report \(PDF 1 MB\)](#)

[Methodological Note \(PDF 0.2 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

## **2022**

Novartis

[Disclosure Report – EUR \(PDF 0.3 MB\)](#)

[Disclosure Report – HRK \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

Sandoz

[Disclosure Report – EUR \(PDF 0.2 MB\)](#)

[Disclosure Report – HRK \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

## **Cyprus**

Below is the disclosure information for Cyprus in English as per EFPIA regulations. In case of questions please [contact us](#).

---

### **2024**

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

### **2023**

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

### **2022**

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

Sandoz

[Methodological Note \(PDF 0.5 MB\)](#)

## **Czech Republic**

Disclosure Report

[Novartis](#)

[Sandoz](#)

## **Denmark**

Disclosure Report

[Novartis](#)

[Sandoz](#)

## **Estonia**

Disclosure Report

[Estonian](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

**Finland**

Disclosure Report

[Novartis](#)

[Sandoz](#)

**France**

Disclosure Report

[French](#)

**Germany**

Disclosure Report

[Novartis](#)

[Sandoz](#)

**Greece**

Disclosure Report

[Greek](#)

**Hungary**

Disclosure Report

[Novartis](#)

[Sandoz](#)

**Iceland**

Disclosure Report

[Novartis](#)

[Sandoz](#)

**Ireland**

Disclosure Report

[English](#)

**Israel**

Disclosure Report

[Hebrew](#)

**Italy**

Disclosure Report

[Italian](#)

For 2023 Sandoz Disclosure reports, please refer to [-Codice sulla Trasparenza | Sandoz Italia](#)

## **Japan**

Disclosure Report

[Novartis](#)

[Sandoz](#)

## **Latvia**

Disclosure Report

[Latvian](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

## **Lithuania**

Disclosure Report

[Lithuanian](#)

## **Luxembourg**

Below is the disclosure information for Luxembourg in English as per EFPIA regulations. In case of questions please [contact us](#).

---

## **2024**

Novartis

[Disclosure Report \(PDF 0.5 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

## **2023**

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

## **2022**

Novartis

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

Sandoz

[Methodological Note \(PDF 0.2 MB\)](#)

## **Malta**

Below is the disclosure information for Malta in English as per EFPIA regulations. In case of questions please [contact us](#).

---

## 2024

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

## 2023

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

## 2022

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

Sandoz

[Methodological Note \(PDF 0.5 MB\)](#)

### Netherlands

Disclosure Report

[Novartis](#)

[Sandoz](#)

### New Zealand

Disclosure Report

[English](#)

### North Macedonia

Below is the disclosure information for North Macedonia in English as per EFPIA regulations. In case of questions please [contact us](#).

---

## 2024

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.4 MB\)](#)

## 2023

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

## **2022**

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

Sandoz

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

## **Norway**

Disclosure Report

[Novartis](#)

[Sandoz](#)

## **Philippines**

Disclosure Report

[English](#)

## **Poland**

Disclosure Report

[Polish](#)

## **Portugal**

Disclosure Report

[Portuguese](#)

## **Romania**

Disclosure Report

[Novartis](#)

[Sandoz](#)

## **Russia**

Disclosure Report

[Novartis](#)

[Sandoz](#)

## **Serbia**

U prilogu se nalaze informacije koje će biti objavljene za Srbiju, na srpskom jeziku, po regulativi EFPIE. U slučaju bilo kakvih pitanja budite slobodni da nas [kontaktirate](#).

---

## 2024

Novartis

[Disclosure Report \(PDF 0.7 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

## 2023

Novartis

[Disclosure Report \(PDF 0.5 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

Sandoz

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.2 MB\)](#)

## 2022

Novartis

[Disclosure Report \(PDF 0.5 MB\)](#)

[Methodological Note \(PDF 0.4 MB\)](#)

Sandoz

[Disclosure Report \(PDF 0.6 MB\)](#)

[Methodological Note \(PDF 0.5 MB\)](#)

## Slovakia

Disclosure Report

[Novartis](#)

[Sandoz](#)

## Slovenia

Spodaj so glede na zahteve EFPIA v slovenskem jeziku objavljeni podatki o prenosih sredstev. V primeru morebitnih vprašanj nas prosimo [kontaktirajte](#).

---

## 2024

Novartis

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

## 2023

Novartis

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

## **2022**

Novartis

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

Sandoz

[Disclosure Report \(PDF 0.4 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

## **South Korea**

Disclosure Report

[Novartis](#)

## **Spain**

Disclosure Report

[Novartis](#)

[Sandoz](#)

## **Sweden**

Disclosure Report

[Novartis](#)

[Sandoz](#)

## **Switzerland**

Disclosure Report

Novartis

[German](#)

[French](#)

Sandoz

[German](#)

[French](#)

## **Turkey**

Disclosure Report

[Novartis](#)

[Sandoz](#)

## UK

Disclosure Report

Novartis

Sandoz

## Ukraine

Disclosure Report

Ukrainian

## United States

Disclosure Report

Novartis

Sandoz

---

**Source URL:** <https://www.novartis.com/investors/reporting-and-transparency-hub/payments-healthcare-professionals>

### List of links present in page

1. <https://www.novartis.com/investors/reporting-and-transparency-hub/payments-healthcare-professionals>
2. <https://www.novartis.com/clinicaltrials>
3. <https://www.novartis.com/investors/reporting-and-transparency-hub/patient-organization-funding>
4. <https://www.efpia.eu/relationships-code/the-efpia-code/>
5. [https://www.novartis.com/sites/novartis\\_com/files/efpia-self-certification-scheme-2025.pdf](https://www.novartis.com/sites/novartis_com/files/efpia-self-certification-scheme-2025.pdf)
6. <https://www.efpia.eu/relationships-code/healthcare-professionals-hcps/>
7. [https://www.novartis.com/sites/novartis\\_com/files/efpia-self-certification-scheme-2024.pdf](https://www.novartis.com/sites/novartis_com/files/efpia-self-certification-scheme-2024.pdf)
8. <https://www.cms.gov/>
9. <https://www.novartis.com/us-en/esg/ethics-risk-and-compliance/payments-hcps-hcos>
10. <https://openpaymentsdata.cms.gov/search>
11. <https://www.novartis.us/corporate-responsibility/payments-hcps-hcos>
12. <https://www.novartis.com.au/about-us/corporate-responsibility/corporate-responsibility-australia/financial-transparency>
13. <https://www.novartis.at/ueber-uns/verantwortung/transparenz-ueber-zahlungen-angehoerige-der-fachkreise>
14. <https://www.sandoz.at/ueber-uns/verantwortung/transparenz-ueber-zahlungen-angehoerige-der-fachkreise>
15. <https://www.novartis.be/fr/transparence-des-paiements-aux-professionnels-de-sante>
16. <https://www.novartis.be/nl/transparantie-van-betalingen-aan-gezondheidszorgverleners>
17. <https://www.sandoz.be/fr/transparence-des-paiements-aux-professionnels-de-sante>
18. <https://www.sandoz.be/nl/transparantie-van-betalingen-aan-gezondheidszorgverleners>
19. <https://www.novartis.com/our-company/contact-us/office-locations>
20. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-bosnia-and-herzegovina-2024.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-bosnia-and-herzegovina-2024.pdf)
21. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-bosnia-and-herzegovina-2024.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-bosnia-and-herzegovina-2024.pdf)
22. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-bosnia-2023.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-bosnia-2023.pdf)
23. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-bosnia-2023.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-bosnia-2023.pdf)
24. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
25. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-bosnia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-bosnia-2022.pdf)
26. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-bosnia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-bosnia-2022.pdf)
27. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-sandoz-bosnia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-bosnia-2022.pdf)
28. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-sandoz-bosnia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-sandoz-bosnia-2022.pdf)
29. <https://declararus.saude.mg.gov.br/>
30. <https://www.novartis.com/bg-bg/esg/transparency>
31. <https://www.sandoz.bg/za-nas/korporativna-otgovornost/prozrachnost>
32. <https://www.novartis.ca/about-us/corporate-responsibility/transparency-voluntary-disclosure-payments-healthcare>
33. <https://www.novartis.ca/fr/about-us/corporate-responsibility/la-transparence-divulgation-volontaire-des-paiements-aux>
34. <https://www.sandoz.ca/transparency-initiative>
35. <https://www.sandoz.ca/fr/initiative-transparence>
36. <https://www.novartis.com/co-es/sobre-novartis/etica-e-integridad>
37. [https://www.novartis.com/about/locations?  
field\\_location\\_business\\_unit\\_target\\_id=All&field\\_location\\_country\\_target\\_id=4586](https://www.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4586)
38. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-croatia-2024.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-croatia-2024.pdf)
39. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-croatia-2024.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-croatia-2024.pdf)

40. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-croatia-2023.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-croatia-2023.pdf)
41. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-croatia-2023.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-croatia-2023.pdf)
42. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
43. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-croatia-2022-eur.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-croatia-2022-eur.pdf)
44. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-croatia-2022-hrk.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-croatia-2022-hrk.pdf)
45. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-croatia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-croatia-2022.pdf)
46. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-sandoz-croatia-2022-eur.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-croatia-2022-eur.pdf)
47. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-sandoz-croatia-2022-hrk.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-croatia-2022-hrk.pdf)
48. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-sandoz-croatia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-sandoz-croatia-2022.pdf)
49. [https://www.novartis.com/about/locations?  
field\\_location\\_business\\_unit\\_target\\_id=All&field\\_location\\_country\\_target\\_id=4501](https://www.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4501)
50. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-cyprus-2024.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-cyprus-2024.pdf)
51. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-cyprus-2024.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-cyprus-2024.pdf)
52. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-cyprus-2023.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-cyprus-2023.pdf)
53. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-cyprus-2023.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-cyprus-2023.pdf)
54. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
55. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-cyprus-2022.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-cyprus-2022.pdf)
56. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-cyprus-novartis-2022.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-cyprus-novartis-2022.pdf)
57. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-cyprus-sandoz-2022.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-cyprus-sandoz-2022.pdf)
58. <https://www.novartis.cz/cs/transparentni-spoluprace-zverejneni>
59. <https://www.sandoz.cz/doing-business-responsibly>
60. <https://www.novartis.dk/om-novartis/hvem-samarbejder-vi-med#ui-id-1=0>
61. <https://www.sandoz.dk/transparency-disclosure-efpia>
62. <https://www.novartis.ee/koostoeoe-tervishoiutoeotajatega>
63. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
64. <https://www.novartis.fi/novartis-yrityksena/yritysvastuu/yhteistyö>
65. <https://www.sandoz.fi/transparency-disclosure-efpia>
66. <https://www.novartis.fr/propos-de-novartis/notre-activite/transparence-des-relations>
67. <https://www.novartis.de/transparenzkodex>
68. <https://www.sandoz.de/ueber-uns/verantwortungsbewusste-geschaeftsfuehrung/transparenz-von-leistungen-fachkreisangehoerige>
69. <https://www.novartis.gr/sustainable-development/business-ethic/disclosure-code>
70. <https://www.novartis.com/hu-hu/egeszsegugyi-szakemberek/atlathatosag>
71. <https://www.sandoz.hu/rolunk/felelos-uzletvitel>
72. <https://frumtok.is/sidareglur/>
73. <https://www.sandoz.dk/transparency-disclosure-efpia>
74. <https://www.novartis.ie/ethics-and-compliance-transparency>
75. [https://www.health.gov.au/Subjects/Finance/Pages/donation\\_reports.aspx](https://www.health.gov.au/Subjects/Finance/Pages/donation_reports.aspx)
76. <https://www.novartis.it/su-di-noi/responsabilita-sociale/etica-persone-ambiente/codice-sulla-trasparenza>
77. <https://www.sandoz.it/su-di-noi/condotta-responsabile-del-business/codice-sulla-trasparenza/>
78. <https://www.novartis.com/jp-ja/esg/transparency>
79. <https://www.sandoz.jp/about-us>
80. <https://www.novartis.com/lv-lv/veselibas-aprupes-specialisti/sadarbiba-ar-veselibas-aprupes-specialistiem>
81. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
82. <https://www.novartis.com/lt-lt/sveikatos-prieziuros-specialistai/bendradarbiavimas-su-sveikatos-prieziuros-specialistais>
83. [https://www.novartis.com/about/locations?  
field\\_location\\_business\\_unit\\_target\\_id=All&field\\_location\\_country\\_target\\_id=4681](https://www.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4681)
84. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-luxembourg-2024.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-luxembourg-2024.pdf)
85. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-luxembourg-2024.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-luxembourg-2024.pdf)
86. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-luxembourg-2023.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-luxembourg-2023.pdf)
87. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-luxembourg-2023.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-luxembourg-2023.pdf)
88. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
89. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-luxembourg-2022.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-luxembourg-2022.pdf)
90. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-luxembourg-novartis-2022.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-luxembourg-novartis-2022.pdf)
91. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-luxembourg-sandoz-2022.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-luxembourg-sandoz-2022.pdf)
92. [https://www.novartis.com/about/locations?  
field\\_location\\_business\\_unit\\_target\\_id=All&field\\_location\\_country\\_target\\_id=4706](https://www.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4706)
93. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-malta-2024.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-malta-2024.pdf)
94. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-malta-2024.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-malta-2024.pdf)
95. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-malta-2023.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-malta-2023.pdf)
96. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-malta-2023.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-malta-2023.pdf)
97. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
98. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-malta-2022.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-malta-2022.pdf)
99. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-malta-novartis-2022.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-malta-novartis-2022.pdf)
100. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-malta-sandoz-2022.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-malta-sandoz-2022.pdf)
101. <https://www.novartis.nl/transparantie-nederland>
102. <https://www.sandoz.nl/over-ons/verantwoord-zakendoen>
103. <https://www.novartis.com.au/about-us/corporate-responsibility/corporate-responsibility-australia-new-zealand/financial->

- transparency-for-new-zealand
104. [https://www.novartis.com/about/locations?  
field\\_location\\_business\\_unit\\_target\\_id=All&field\\_location\\_country\\_target\\_id=4701](https://www.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4701)
  105. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-north-macedonia-2024.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-north-macedonia-2024.pdf)
  106. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-north-macedonia-2024.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-north-macedonia-2024.pdf)
  107. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-north-macedonia-2023.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-north-macedonia-2023.pdf)
  108. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-north-macedonia-2023.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-north-macedonia-2023.pdf)
  109. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
  110. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-north-macedonia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-north-macedonia-2022.pdf)
  111. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-northmacedonia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-northmacedonia-2022.pdf)
  112. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-sandoz-northmacedonia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-northmacedonia-2022.pdf)
  113. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-sandoz-north-macedonia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-sandoz-north-macedonia-2022.pdf)
  114. <https://www.novartis.com/no-no/om-oss/pengeoverforing-til-helsetjenesten>
  115. <https://www.sandoz.no/transparency-disclosure-efpia>
  116. <https://www.novartis.com/ph-en/esg/financial-transparency-philippines>
  117. <https://www.novartis.pl/wspolpraca-z-przedstawicielami-zawodow-medycznych-oraz-organizacjami-ochrony-zdrowia#ui-id-1=0>
  118. <https://www.novartis.pt/transferencias-de-valor-profissionais-e-organizacoes-de-saude>
  119. <https://www.novartis.com.ro/contributia-noastra/transparenta>
  120. <https://www.sandoz.ro/despre-noi/etica-si-conformitate>
  121. <https://www.novartis.ru/about-us/corporate-responsibility/general-disclosure>
  122. <https://www.sandoz.ru/o-kompanii/otvetstvennoe-vedenie-biznesa/general-disclosure>
  123. [https://www.novartis.com/about/locations?  
field\\_location\\_business\\_unit\\_target\\_id=All&field\\_location\\_country\\_target\\_id=4801](https://www.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4801)
  124. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-serbia-2024.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-serbia-2024.pdf)
  125. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-serbia-2024.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-serbia-2024.pdf)
  126. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-serbia-2023.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-serbia-2023.pdf)
  127. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-serbia-2023.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-serbia-2023.pdf)
  128. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-sandoz-serbia-2023.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-serbia-2023.pdf)
  129. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-sandoz-serbia-2023.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-sandoz-serbia-2023.pdf)
  130. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-serbia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-serbia-2022.pdf)
  131. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-serbia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-serbia-2022.pdf)
  132. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-sandoz-serbia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-serbia-2022.pdf)
  133. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-sandoz-serbia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-sandoz-serbia-2022.pdf)
  134. <https://www.novartis.sk/o-nas/spolocenska-zodpovednost/transparentnost-v-platbach-zdravotnickym-pracovnikom>
  135. <https://www.sandoz.sk/o-nas/transparentna-spolupraca>
  136. [https://www.novartis.com/about/locations?  
field\\_location\\_business\\_unit\\_target\\_id=All&field\\_location\\_country\\_target\\_id=4826](https://www.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4826)
  137. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-slovenia-2024.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-slovenia-2024.pdf)
  138. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-slovenia-2024.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-slovenia-2024.pdf)
  139. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-slovenia-2023.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-slovenia-2023.pdf)
  140. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-slovenia-2023.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-slovenia-2023.pdf)
  141. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
  142. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-novartis-slovenia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-slovenia-2022.pdf)
  143. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-novartis-slovenia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-novartis-slovenia-2022.pdf)
  144. [https://www.novartis.com/sites/novartis\\_com/files/payment-disclosure-sandoz-slovenia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-slovenia-2022.pdf)
  145. [https://www.novartis.com/sites/novartis\\_com/files/methodological-note-sandoz-slovenia-2022.pdf](https://www.novartis.com/sites/novartis_com/files/methodological-note-sandoz-slovenia-2022.pdf)
  146. <https://www.novartis.com/kr-ko/esg/corporate-responsibility/doing-business-responsibility>
  147. <https://www.novartis.es/sobre-novartis/responsabilidad-social/practica-empresarial-responsable/transparentia-en-las>
  148. <https://www.sandozfarma.es/sobre-sandoz/responsabilidad-social-corporativa/practica-empresarial-responsable/transferencias-de>
  149. <https://www.novartis.se/om-novartis/vart-ansvar/transparent-samarbete>
  150. <https://www.sandoz.se/transparency-disclosure-efpia>
  151. <https://www.novartis.ch/offenlegung>
  152. <https://www.novartis.com/ch-fr/societe-environnement/publication-des-transferts-de-valeurs>
  153. <https://www.sandoz-pharmaceuticals.ch/de/ueber-uns/verantwortungsvolle-geschaeftsfuehrung/offenlegung-der-geldwerten-leistungen-fachpersonen>
  154. <https://www.sandoz-pharmaceuticals.ch/fr/ueber-uns/verantwortungsvolle-geschaeftsfuehrung/publication-des-transferts-des-valeurs-aux>
  155. <https://www.novartis.com.tr/hakkimizda/kurumsal-sorumluluk>
  156. <https://www.sandoz.com.tr/hakkimizda/yapma-sorumlulugumuz>
  157. <https://www.novartis.com/uk-en/esg/transparency/healthcare-professional-payment-transparency>
  158. <https://www.sandoz.uk.com/about-us/transparency/>
  159. <https://aprad.org.ua/tematichni-rozdili/rozkrittya-informatsiyi/>
  160. <https://www.pharma.us.novartis.com/corporate-responsibility/physician-payments-sunshine-act>
  161. <https://www.us.sandoz.com/about-us/doing-business-responsibly>